Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled date : 2020 - 12 - 04 save search
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
Published: 2020-12-04 (Crawled : 21:03) - globenewswire.com
FATE | $5.28 -1.86% -1.89% 2.1M
|
Health Technology
| Email alert
Add to watchlist
positive phase 3 phase 1 phase 2 t-cell
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Published: 2020-12-04 (Crawled : 15:00) - biospace.com/
DTIL | $11.5 -10.65% -11.91% 220K
|
Health Technology
|
| O: -4.69%
H: 2.36%
C: -14.82%
positive results leukemia trial phase 3 phase 1 phase 2 t-cell
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.